Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
14 juin 2024 07h00 HE | Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
JJ_Logo_SingleLine_Red_RGB.png
Findings from landmark RESONATE-2 study confirm sustained survival benefit of IMBRUVICA® (ibrutinib) for first-line chronic lymphocytic leukaemia treatment with up to 10 years follow-up
14 juin 2024 03h00 HE | Janssen Cilag International NV
RESONATE-2 data presented at the 2024 European Hematology Association (EHA) Congress provide longest-term outcomes and safety data ever reported for a monotherapy BTK inhibitor, with a median PFS of...
IN8bioLogo.jpg
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
13 juin 2024 16h01 HE | IN8bio, Inc
IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100
CERo color.jpg
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
13 juin 2024 08h15 HE | CERo Therapeutics Holdings, Inc.
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO)...
OBI Logo.jpg
浩鼎啟動OBI-992一/二期臨床試驗
12 juin 2024 05h55 HE | OBI Pharma Inc.
OBI-992以TROP2為標靶的ADC 研究目的在評估治療多種實體腫瘤的安全性和有效性 台灣台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎 (4174.TWO)今(12)日宣布,正式啟動OBI-992的人體一/二期臨床試驗。OBI-992係浩鼎自行研發,以TROP2為標靶所設計的抗體藥物複合體(antibody-drug conjugate,...
OBI Logo.jpg
浩鼎启动OBI-992一/二期临床试验
12 juin 2024 05h55 HE | OBI Pharma Inc.
OBI-992以TROP2为标靶的ADC 研究目的在评估治疗多种实体肿瘤的安全性和有效性 台湾台北, June 12, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎 (4174.TWO)今(12)日宣布,正式启动OBI-992的人体一/二期临床试验。 OBI-992系浩鼎自行研发,以TROP2为标靶所设计的抗体药物复合体(antibody-drug...
logo.jpg
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
12 juin 2024 05h00 HE | Helsinn Healthcare S.A.
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...
SERMONIX NEW LOGO JPEG (2).jpg
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Paper Examining Lasofoxifene’s Preclinical Effects on Aromatase Inhibitor Resistant Non-ESR1 Mutated Breast Cancer
10 juin 2024 10h17 HE | Sermonix Pharmaceuticals Inc.
In preclinical mouse models, results suggested lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumorsPhase 3 ELAINE-3 study is currently investigating...